Trials / Completed
CompletedNCT00392002
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,000 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the burden of disease in GERD patients of prescription therapy'
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole |
Timeline
- Start date
- 2005-10-01
- Completion
- 2007-05-01
- First posted
- 2006-10-25
- Last updated
- 2008-01-25
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00392002. Inclusion in this directory is not an endorsement.